BMY

Bristol Myers Squibb's stock experienced several notable events including a Q1 CY2026 earnings beat, reaffirmed FY 2026 guidance, and growth portfolio momentum. Opdivo revenue declined, and the Eliquis patent cliff remains a significant risk. The EU approved Sotyktu, and Eliquis became available through the Mark Cuban Cost Plus Drug Company. Positive trial results were reported for Camzyos, Cobenfy, izalontamab brengitecan, and luspatercept. The FDA accepted the Iberdomide NDA, and the company reported Q4 and full-year 2025 financial results. Bristol Myers Squibb announced a collaboration with Microsoft, and EVP David V. Elkins sold 30,000 shares of the company's stock.